| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C0001675> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C0013072> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C0026062> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C0085415> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C0086582> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C0087113> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C0205847> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C0600378> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C2985546> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C3850123> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C4704925> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/34863332_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA. Electronic address: temesgen.zelalem@mayo.edu.\', \'Mayo Clinic, Division of Pulmonary, Allergy and Sleep Medicine, Jacksonville, FL, USA.\', \'Hennepin Healthcare Research Institute, Minneapolis, MN, USA.\', \'Atrium Health, Charlotte, NC, USA.\', \'Mayo Clinic, Division of Infectious Diseases, Jacksonville, FL, USA.\', \'Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Grady Memorial Hospital, Atlanta, GA, USA.\', \'Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Rollins School of Public Health and Emory Vaccine Center, Atlanta, GA, USA.\', \'Mayo Clinic Arizona, Division of Infectious Diseases, Phoenix, AZ, USA.\', \'BioSymetrics, New York, NY, USA.\', \'CTI, Clinical Trial Services, Covington, KY, USA.\', \'Humanigen, Burlingame, CA, USA.\', \'Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Ahmed_Omar> <https://research.tib.eu/covid-19/entity/Aronstein_William_S> <https://research.tib.eu/covid-19/entity/Badley_Andrew_D> <https://research.tib.eu/covid-19/entity/Baker_Jason> <https://research.tib.eu/covid-19/entity/Burger_Charles_D> <https://research.tib.eu/covid-19/entity/Catterson_Victoria_M> <https://research.tib.eu/covid-19/entity/Chappell_Dale> <https://research.tib.eu/covid-19/entity/Chappell_Gabrielle> <https://research.tib.eu/covid-19/entity/Durrant_Cameron> <https://research.tib.eu/covid-19/entity/Kelley_Colleen_F> <https://research.tib.eu/covid-19/entity/Libertin_Claudia_R> <https://research.tib.eu/covid-19/entity/Marconi_Vincent_C> <https://research.tib.eu/covid-19/entity/Orenstein_Robert> <https://research.tib.eu/covid-19/entity/Polk_Christopher> <https://research.tib.eu/covid-19/entity/Temesgen_Zelalem>
?:doi	S2213-2600(21)00494-X10.1016/S2213-2600(21)00494-X
?:doi	<https://research.tib.eu/covid-19/entity/S2213-2600%2821%2900494-X10.1016/S2213-2600%2821%2900494-X>
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Clinical_Trial%2C_Phase_III> <https://research.tib.eu/covid-19/entity/Journal_Article> <https://research.tib.eu/covid-19/entity/Randomized_Controlled_Trial> <https://research.tib.eu/covid-19/entity/Research_Support%2C_N.I.H.%2C_Extramural> <https://research.tib.eu/covid-19/entity/Research_Support%2C_Non-U.S._Gov%27t>
?:journal	The Lancet. Respiratory medicine
is ?:pmid of	<https://research.tib.eu/covid-19/entity/34863332>
?:pmid	<https://research.tib.eu/covid-19/entity/34863332>
?:pmid	34863332
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	-1.0
?:rankingScore_hIndex	-1
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/C0003250_COEXISTS_WITH_C1634625> <https://research.tib.eu/covid-19/entity/C0038317_ADMINISTERED_TO_C0030705>
?:title	Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2022

Property

Value

is ?:annotates of

?:authorAffiliation

[\'Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA. Electronic address: temesgen.zelalem@mayo.edu.\', \'Mayo Clinic, Division of Pulmonary, Allergy and Sleep Medicine, Jacksonville, FL, USA.\', \'Hennepin Healthcare Research Institute, Minneapolis, MN, USA.\', \'Atrium Health, Charlotte, NC, USA.\', \'Mayo Clinic, Division of Infectious Diseases, Jacksonville, FL, USA.\', \'Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Grady Memorial Hospital, Atlanta, GA, USA.\', \'Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Rollins School of Public Health and Emory Vaccine Center, Atlanta, GA, USA.\', \'Mayo Clinic Arizona, Division of Infectious Diseases, Phoenix, AZ, USA.\', \'BioSymetrics, New York, NY, USA.\', \'CTI, Clinical Trial Services, Covington, KY, USA.\', \'Humanigen, Burlingame, CA, USA.\', \'Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.\']

?:citedBy